Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61971 |
CHMFL-PI4K-127
|
Others | Others |
CHMFL-PI4K-127 (compound 15g) 是具有口服活性、高选择性的PfPI4K(恶性疟原虫 PI4K 激酶)抑制剂(IC50= 0.9 nM)。CHMFL-PI4K-127 对 3D7 恶性疟原虫表现出较强的抑制活性(EC50= 25.1 nM)。CHMFL-PI4K-127 具有抗疟疾作用。 | |||
TQ0009 |
UCB9608
|
PI4K | PI3K/Akt/mTOR signaling |
UCB9608 是选择性、可口服的 PI4KIIIβ 抑制剂,IC50=11 nM,对其选择性高于 PI3KC2 α,β 和 γ。它能够增加代谢稳定性,具有良好的药代动力学特征,是一种免疫抑制剂。 | |||
T16125 |
MMV390048
|
Parasite; PI4K | Microbiology/Virology; PI3K/Akt/mTOR signaling |
MMV390048 是一种抗疟药,是一种新型化学疟原虫 PI4K 抑制剂。它与疟原虫 PI4K 的 ATP 结合位点结合,不与除人类 PIP4K2C 外的其他恶性疟原虫和人类激酶结合。 | |||
T16967 |
T-00127_HEV1
|
PI4K | PI3K/Akt/mTOR signaling |
T-00127_HEV1 是有效的phosphatidylinositol 4-kinase III beta 抑制剂,IC50为 60 nM。 | |||
T12454 |
PI-273
|
Apoptosis; PI4K | Apoptosis; PI3K/Akt/mTOR signaling |
PI-273 是一种可逆的特异性磷脂酰肌醇 4-激酶抑制剂,IC50为 0.47 μM。它可抑制乳腺癌细胞的增殖,阻断细胞周期并诱导细胞凋亡。 | |||
T16530 |
BF738735
|
Antiviral; PI4K | Immunology/Inflammation; PI3K/Akt/mTOR signaling |
BF738735 是有效的磷脂酰肌醇 4-激酶 IIIβ 抑制剂,IC50为 5.7 nM。 | |||
T5421 |
KDU691
|
Parasite; PI4K | Microbiology/Virology; PI3K/Akt/mTOR signaling |
KDU691 是一种咪唑吡嗪类药物,对血阶段的裂殖体、配子体和肝期具有较强的抗寄生虫活性,它是 PI4K 抑制剂,选择性抑制双氢青蒿素预处理的恶性疟原虫。 | |||
T12468 |
PI4KIIIbeta-IN-10
|
PI3K; PI4K | PI3K/Akt/mTOR signaling |
PI4KIIIbeta-IN-10 是PI4KIIIβ抑制剂,IC50=3.6 nM。 | |||
T2616 |
PIK-93
PIK 93 |
ATM/ATR; DNA-PK; Virus Protease; PI3K; Carbonic Anhydrase; PI4K; mTOR; HSV | DNA Damage/DNA Repair; Metabolism; Microbiology/Virology; PI3K/Akt/mTOR signaling |
PIK-93 是一种合成的PI4KIIIβ抑制剂,IC50值为 19 nM,同时可抑制PI3Kγ和PI3Kα的活性,IC50值分别为 16 nM 和 39 nM。 | |||
T12469 |
PI4KIIIbeta-IN-9
|
PI3K; PI4K | PI3K/Akt/mTOR signaling |
PI4KIIIbeta-IN-9 是一种 PI4KIIIβ抑制剂,其 IC50=7 nM。它也抑制 PI3Kδ (IC50:125 nM) 和 PI3Kγ (IC50:1046 nM)。 | |||
T4220 |
BQR-695
BQR695,NVP-BQR695 |
PI3K; Parasite; PI4K | Microbiology/Virology; PI3K/Akt/mTOR signaling |
BQR-695 (NVP-BQR695) 是一种磷脂酰肌醇 4-激酶抑制剂,对于人类和疟原虫 PI4KIIIβ 的 IC50值分别为 80 和 3.5 nM。 | |||
T27499 |
GSK-A1
|
HCV Protease; PI4K | Microbiology/Virology; PI3K/Akt/mTOR signaling; Proteases/Proteasome |
GSK-A1 是 III 型磷脂酰肌醇 4-激酶 PI4KA 选择性抑制剂,pIC50为 8.5-9.8,抑制 PtdIns(4,5)P2 再合成,IC50约为 3 nM。GSK-A1有效降低 PtdIns(4)P 的水平,而对 PtdIns(4,5)P2 没影响。GSK-A1在抗丙型肝炎病毒方面有研究的潜力。 | |||
T19840 |
GSK-F1
PI4KA inhibitor-F1 |
PI4K | PI3K/Akt/mTOR signaling |
GSK-F1 (PI4KA inhibitor-F1) 是一种新型强效 PI4KA 抑制剂。 | |||
T12467 |
PI4KIII beta inhibitor 3
|
PI3K | PI3K/Akt/mTOR signaling |
PI4KIII beta inhibitor 3 is a novel and high effective inhibitor of PI4KIIIβ (IC50 of 5.7 nM). | |||
T64106 |
PI4KIIIbeta-IN-11
|
Others | Others |
PI4KIIIbeta-IN-11 是一种 PI4KIIIβ 抑制剂 (平均 pIC50=9.1),能够用于研究 RNA 病毒和恶性疟原虫引起的疾病。 | |||
T13246 |
UCT943
|
Parasite; PI4K | Microbiology/Virology; PI3K/Akt/mTOR signaling |
UCT943是恶性疟原虫PI4K 的抑制剂(IC50 = 23 nM)。 | |||
T2685 |
KU-55933
ATM Kinase Inhibitor |
ATM/ATR; DNA-PK; PI3K; mTOR; Autophagy | Autophagy; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
KU-55933 (ATM Kinase Inhibitor) 是一种 ATM 抑制剂,IC50和 Ki 值分别为 12.9 和 2.2 nM。它对 ATM 的选择性比对 PI3K/PI4K、 DNA-PK、ATR 和 mTOR 高。 | |||
T71694 |
BRD73842
|
Others | Others |
BRD73842 is an inhibitor of Plasmodium PI4K. | |||
T15651 | KDU731 | Others | Others |
KDU731 is a promising drug candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety. KDU731is an orally active C. parvum inhibitor of PI4K (IC50: 25 nM). KDU731 blocks Cryptosporidium infection in vitro and in vi | |||
T79876 |
EDI048
|
PI4K | PI3K/Akt/mTOR signaling |
EDI048(化合物1.16)作为一种针对Cryptosporidium PI4K的有效口服抑制剂,其主要应用于隐孢子虫病研究领域。 | |||
T25826 |
MMV024101
MMV-024101,TCMDC 134293,TCMDC134293,TCMDC-134293,MMV 024101 |
Others | Others |
MMV024101 is a PI4K inhibitor. MMV024101 exhibits submicromolar potency against P. falciparum NF54 (IC50 =543 nM), low aqueous solubility (<5 μM), and rapid clearance by mouse liver microsomes with only 2% of parent compound remaining after 30 min of incu | |||
T68485 |
Apilimod HCl
|
Others | Others |
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions. It reduces the number of SARS-CoV-2-infected hiPSC-derived pneumocyte-like cells by 85% and inhibits SARS-CoV-2 replication in donor lung tissue. It also exhibits selective cytotoxicity in B-cell non-Hodgkin lymphoma ... |